"Designing Growth Strategies is in our DNA"
Relapsing neuromyelitis optica spectrum disorder, also called neuromyelitis optica or Devic disease, is an autoimmune inflammatory disorder that affects the central nervous system. It is categorized by axonal damage and serious immune-mediated demyelination preferentially targeting spinal cord and optic nerves. Relapsing neuromyelitis optica spectrum disorder is often confused with multiple sclerosis during the early stage. The symptoms of relapsing neuromyelitis optica spectrum disorder are either myelitis or optic neuritis, resulting in pain inside the eye and spine or limbs, respectively.
The standard treatment for acute attacks is high-dose corticosteroids such as methylprednisolone. Plasma exchange can also be done for patients experiencing severe attacks and are not responding to corticosteroids. Drugs such as azathioprine, rituximab, and mycophenolate mofetil are often prescribed for the long term management of neuromyelitis optica.
Lack of drugs for the proper treatment, rising prevalence of the disorder, and active government support has resulted in significant investment by pharmaceutical companies and research institutes for clinical study on the relapsing neuromyelitis optica spectrum disorder. For instance; Satralizumab, a type of interleukin is being studied by F. Hoffmann-La Roche Ltd. and is currently in phase 3 clinical trials for the treatment of relapsing neuromyelitis optica spectrum disorder.
To know how our report can help streamline your business, Speak to Analyst
At present, around 41% of the pipeline candidates for relapsing neuromyelitis optica spectrum disorder are in phase 1 clinical stage. More than half of the studies are sponsored by the pharmaceutical industry.
The report on ‘Relapsing Neuromyelitis Optica Spectrum Disorder – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Relapsing Neuromyelitis Optica Spectrum Disorder. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Relapsing Neuromyelitis Optica Spectrum Disorder.
The report on ‘Relapsing Neuromyelitis Optica Spectrum Disorder – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.